Fragmentation of genomic data sources
Commercial teams face a daunting array of obstacles: fragmented data sources, a lack of standardization, inconsistent data quality, and the sheer volume of information.
Lack of industry standards
Each data provider often develops its own standards, leading to inconsistencies and requiring substantial investment when combining multiple sources.
Unstructured data
Critical clinical information is frequently buried in lab notes, demanding extensive effort to interpret and structure into usable data.
Incomplete patient records
Missing or incorrect values for coding and HCP information can hinder comprehensive understanding.
Difficulty in pinpointing treating physicians
Up to 100% of physicians associated with lab data may not be the treating physician in complex populations, leading to wasted outreach efforts.
Unparalleled Rare Disease Data Access & Expertise
Prognos has the most comprehensive data partnerships in rare disease, providing access to deep genomic data, including reported phenotypes, HGVS segments, cytogenetic location, pathogenicity, chromosome, and allele. We are the exclusive partner of this data in life sciences. Our transparent partnerships with leading US genomics labs ensure access to the majority of US rare disease testing data.
Data Mastery: Integration, Harmonization, Enrichment
Our proprietary technology, powered by advanced ML/AI, meticulously integrates, cleanses, standardizes, and enriches raw lab data. This ensures the data is accurate, consistent, and immediately usable for your commercial applications. This includes:
-
Interpretation
Extracting critical clinical information from unstructured lab notes, such as testing methodology, cancer stage, and gene tested.
-
Harmonization
Standardizing test names, units, and platforms across various labs for an apples to apples view.
-
Enrichment
Filling gaps in missing or unstructured data through AI/ML programming, including HCP NPI and specialty enrichment, to maximize the value of each lab record.
Flexible Data Delivery: Accelerating Time to Treatment
In rare diseases, every moment counts for patients. Prognos delivers data with the speed your commercial teams require to optimize engagement, accelerate diagnosis, and initiate treatment faster. Our flexible delivery options include:
-
Daily deliveries
For the most immediate insights and rapid response.
-
Twice-weekly deliveries
Balancing speed with efficient integration into your workflows.
-
Early weekly deliveries
Gain a crucial competitive edge in patient identification and HCP engagement.
Key Use Cases for Rare Disease Commercial Teams:
-
Rare Disease Patient Finder
Our specialized tools enable highly targeted identification of rare and ultra-rare patients, a critical step for therapy launch and access.
-
Precision Marketing
Engage HCPs earlier in the patient journey to help ensure appropriate treatment for patients with rare conditions.
-
HCP Segmentation and Targeting
Build dynamic profiles to segment the market and align across channels, identifying the most relevant specialists for your rare disease therapies.
-
Alerts and Next Best Action
Receive timely alerts about newly identified patients or changes in patient status, allowing for proactive outreach and next best action strategies.
-
Patient Journey Support
Understand the entire patient journey for rare diseases, from diagnosis to treatment, identifying leverage points for sales, marketing, and market access interventions.
-
Media Targeting
Improve media targeting with lab-derived audience segments, ensuring your digital campaigns reach the most relevant HCPs.
.png?height=2000&name=image%20(17).png)
RARE DISEASE CASE STUDY:
Maximizing Actionable Patient Identifications
Want to see how Prognos Health helped a pharmaceutical company maximize actionable patient identifications for a rare skeletal dysplasia?
Challenge:
A pharmaceutical company launching a first-line therapy for a rare skeletal dysplasia struggled to identify eligible patients using claims data, which was inefficient in pinpointing individuals with confirmed diagnoses and specific genetic mutations. They needed a better way to link patients to relevant specialists.
Solution:
The company evaluated Prognos Health against a competitor for lab-data based patient identification solutions. Prognos Health distinguished itself by prioritizing 100% actionable data, ensuring every identified patient was linked to a relevant specialist.
Analysis:
While the competitor initially provided more raw patient counts, Prognos Health delivered significantly more actionable insights. This resulted in a higher return on investment for the client due to a lower cost per actionable patient, avoidance of wasted resources on non-actionable leads, and 100% incremental data identifying previously unknown treating providers.
Results:
-
Prognos Health
Identified 13 patients with the target genetic mutation through lab data, all linked to 13 unique HCPs. 8 of these HCPs were designated as "Providers of Interest" (POIs) based on the client's specialist criteria.
-
Competitor
Identified 20 patients with the mutation through lab data, but only 3 were linked to POIs.